Contribution of nosocomial transmission to *Klebsiella pneumoniae* neonatal sepsis in Africa and South Asia: analysis of infection clusters inferred from pathogen genomics and temporal data

Short title: Transmission of *Klebsiella pneumoniae* causing invasive disease in neonatal units

Erkison Ewomazino Odih[1], Jabir A Abdulahi[2], Anne V Amulele[3], Matthew Bates[4], Eva Heinz[5,6], Weiming Hu[7], Kajal Jain[8], Rindidzani Magobo[9,10], Courtney P Olwagen[11], John M Tembo[12], Tolbert Sonda[13], Jonathan Strysko[14,15], Caroline C Tigoi[3], Kyle Bittinger[7,16,17], Jennifer Cornick[18,19], Ebenezer Foster-Nyarko[1], Wilson Gumbi[3], Steven M Jones[7], Chileshe L Musyani[20,21], Carolyn M McGann[22,16], Ahmed M Moustafa[7,16,17], Patrick Musicha[19,23], James CL Mwansa[24], Moreka L Ndumba[3], Thomas D Stanton[25,26], Donwilliams O Omuoyo[3], Oliver Pearse[19,23], Laura T Phillips[1], Paul J Planet[16,17,27], Charlene MC Rodrigues[1,28,29], Fatou Secka[1], Kirsty Sands[30,31], Erin Theiller[17], Allan M Zuza[19,32], Sulagna Basu[33], Grace J Chan[34], Kenneth C Iregbu[35,36], Jean-Baptiste Mazarati[37,38], Semaria Solomon Alemayehu[39], Timothy R Walsh[30,40], Rabaab Zahra[41,42], Angela Dramowski[43], Sombo Fwoloshi[44], Appiah-Korang Labi[45], Lola Madrid[2,46], Noah Obeng-Nkrumah[47], David Ojok[48], Boaz D Wadugu[49], Andrew C Whitelaw[50,51], Anudita Bhargava[52], Atul Jindal[53], Ramesh K Agarwal[8], Alexander M Aiken[2], James A Berkley[54,55], Susan E Coffin[16,56], Nicholas A Feasey[19,27], Nelesh P Govender[9, 32], Davidson H Hamer[57,58], Shabir A Madhi[11,59], M Jeeva Sankar[8], Kelly L Wyres[1,25,26], Kathryn E Holt[1,25,*]

1 Department of Infection Biology, London School of Hygiene and Tropical Medicine, London, UK
2 Department of Infectious Disease Epidemiology and International Health, London School of Hygiene and Tropical Medicine, London, UK
3 Bioscience Department, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
4 School of Natural Sciences, University of Lincoln, Lincoln, UK
5 Strathclyde Institute of Pharmacy & Biomedical Sciences, University of Strathclyde, Glasgow, UK
6 Parasites and Microbes Program, Wellcome Sanger Institute, Hinxton, UK
7 Division of Gastroenterology, Hepatology, and Nutrition, Children's Hospital of Philadelphia, Philadelphia, USA
8 Division of Neonatology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India
9 National Institute for Communicable Diseases, a Division of the National Health Laboratory Service, Johannesburg, South Africa
10 Division of Public Health, Societies and Belonging, Human Sciences Research Council, Pretoria, South Africa
11 South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
12 Infectious Diseases, HerpeZ, Lusaka, Zambia
13 Bioinformatics Unit, Kilimanjaro Clinical Research Institute, Moshi, Tanzania
14 Botswana-University of Pennsylvania Partnership, University of Pennsylvania, Gaborone, Botswana
15 Division of General Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
16 Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
17 Center for Microbial Medicine, Children's Hospital of Philadelphia, Philadelphia, USA
18 Clinical Infection, Microbiology and Immunology, University of Liverpool, Liverpool, UK
19 Malawi Liverpool Wellcome Programme, Kamuzu University of Health Sciences, Blantyre, Malawi
20 Antimicrobial Resistance Unit, Zambia National Public Health Institute, Lusaka, Zambia
21 Levy Mwanawasa Medical University, Lusaka, Zambia
22 Division of Neonatology, Children's Hospital of Philadelphia, Philadelphia, USA
23 Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK
24 Directorate of Research and Post Graduate Studies, Lusaka Apex Medical University, Lusaka, Zambia

25 Department of Infectious Diseases, School of Translational Medicine, Monash University, Melbourne, Australia
26 Centre to Impact AMR, Monash University, Clayton, Victoria, Australia
27 The School of Medicine, University of St Andrews, St Andrews, UK
28 Department of Paediatrics, Imperial College Healthcare NHS Trust, London, UK
29 Pathogen Genomics Programme, UK Health Security Agency, London, UK
30 Ineos Oxford Institute for Antimicrobial Research, University of Oxford, Oxford, UK
31 Department of Medical Microbiology, Division of Infection and Immunity, Cardiff University, Cardiff, UK
32 Wits Mycology Division, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
33 Division of Bacteriology, ICMR-National Institute for Research in Bacterial Infections (formerly ICMR-NICED), Kolkata, India
34 Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, USA
35 Medical Microbiology, University of Abuja, Abuja, Nigeria
36 National Hospital Abuja, Abuja, Nigeria
37 Health Sciences, INES-RUHENGERI, Musanze, Rwanda
38 INES Centre for Genomic Biology, Musanze, Rwanda
39 Department of Microbiology, Immunology and Parasitology, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia
40 International Centre for Antimicrobial Resistance Solutions, Copenhagen, Denmark
41 Department of Microbiology, Quaid-i-Azam University, Islamabad, Pakistan
42 Department of Clinical Microbiology, School of Medicine, Trinity College Dublin, St James's Hospital, Dublin 8, Ireland
43 Department of Paediatrics and Child Health, Stellenbosch University, Cape Town, South Africa
44 University Teaching Hospital, University of Zambia, School of Medicine, Lusaka, Zambia
45 Department of Medical Microbiology, University of Ghana Medical School, Accra, Ghana
46 College of Health and Medical Sciences, Haramaya University, Harar, Ethiopia
47 Department of Medical Laboratory Sciences, School of Biomedical and Allied Health Sciences, College of Health Sciences, University of Ghana, Accra, Ghana
48 Central Laboratory, Centre for Infectious Disease Research in Zambia, Lusaka, Zambia
49 Biotechnology Laboratory, Kilimanjaro Clinical Research Institute, Moshi, Tanzania
50 Medical Microbiology and Immunology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
51 National Health Laboratory Service, Tygerberg Hospital, Cape Town, South Africa
52 Microbiology, All India Institute of Medical Sciences, Raipur, India
53 Pediatrics, All India Institute of Medical Sciences, Raipur, India
54 Nuffield Department of Medicine, University of Oxford, Oxford, UK
55 Clinical Research Department, KEMRI/Wellcome Trust Research Programme, Kilifi, Kenya
56 Division of Infectious Diseases, Children's Hospital of Philadelphia, Philadelphia, USA
57 Department of Global Health, Boston University School of Public Health, Boston, MA, USA
58 Section of Infectious Diseases, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA
59 Wits Infectious Diseases and Oncology Research Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

* Corresponding author
Email: kat.holt@lshtm.ac.uk

Abstract

Background

Klebsiella pneumoniae is the leading cause of sepsis among neonates in low- and middle-income countries (LMICs) in Africa and Asia, contributing substantially to the overall burden of antimicrobial resistant (AMR) infections and mortality among neonates globally. Pathogen sequencing has been used to investigate case clusters and confirm nosocomial transmission in a small number of neonatal units. Here we utilise pathogen sequence data to estimate the fraction of *K. pneumoniae* neonatal sepsis attributable to nosocomial transmission in African and South Asian countries.

Methods and Findings

We estimated the proportion of invasive *K. pneumoniae* disease involved in nosocomial transmission clusters in a given neonatal unit, using single-linkage clustering based on pairwise temporal and genetic distances estimated from bacterial whole-genome sequences aggregated from 10 contributing studies. Analysing 1,523 *K. pneumoniae* isolates from 27 units in 13 countries in Africa and South Asia between 2013 and 2023, we inferred 156 nosocomial transmission clusters, ranging from 2 to 188 neonates each (83 of the clusters comprised ≥3 cases). Overall, we estimated that 1,035 neonatal infections (68.0%) were part of nosocomial transmission clusters. Excluding the first infection in each cluster as a potential index case, we estimate at least 879 (57.7%) infections were acquired via nosocomial transmission. Sensitivity analyses showed that results were robust to the choice of genetic distance estimation methods and thresholds used to define clusters, and cluster estimates were stable over temporal distance thresholds ranging from 2 to 8 weeks. Isolates were mostly extended-spectrum beta-lactamase (ESBL) producers (90.9%) and included 172 multi-locus sequence types (STs). Fourteen STs, including several globally recognised multidrug-resistant lineages, were associated with transmission clusters at multiple units and these were collectively responsible for two-thirds of all infections. Carriage of

carbapenemase genes (adjusted odds ratio, aOR = 2.08 [95% confidence interval, CI: 1.04–4.14], p=0.02) and ESBL genes (aOR = 2.48 [95% CI: 1.26–4.90] p=0.006) were significantly positively associated with transmission.

Conclusions

Nosocomial transmission contributes to a substantial proportion of *K. pneumoniae* sepsis in neonatal care units in Africa and South Asia. Reducing transmission within these settings through improved infection prevention and control and other measures could substantially reduce the neonatal sepsis burden. A high burden of transmission clusters is associated with the same drug-resistant lineages that are recognised as high-risk clones associated with hospital outbreaks in high-income countries, indicating global connectivity of the AMR pathogen population.

Keywords: *Klebsiella pneumoniae*; neonatal sepsis; transmission; outbreak; Africa; South Asia; pathogen sequencing; genomics

Author Summary

Why Was This Study Done?

- *Klebsiella pneumoniae* is the leading cause of sepsis among neonates in low- and middle-income countries (LMICs) in Africa and Asia, and the infections are difficult to treat due to rising rates of antimicrobial resistance.
- Invasive bacterial diseases are typically transmitted to neonates from their mothers before, during or soon after birth (vertical transmission) or from the hospital environment and healthcare workers (horizontal transmission).
- The fraction of *K. pneumoniae* neonatal sepsis cases attributable to horizontal transmission is unknown, but this information is important to understand the role of infection prevention and control (IPC) measures in lowering disease burden.

What Did the Researchers Do and Find?

- We developed a simple method to detect transmission clusters from genetic and temporal distance data and found the method to be robust to the choice of genetic and temporal distance thresholds.
- We applied this method to detect transmission clusters among 1,523 *K. pneumoniae* neonatal sepsis cases from 10 studies and 27 hospitals across Africa and South Asia.
- We estimate over half of sepsis cases (68.0%) were part of a transmission cluster, and by excluding the hypothetical index case for each cluster we estimate at least 57.7% of infections were acquired via nosocomial transmission.
- Most of the isolates (90.9%) were extended-spectrum beta-lactamase (ESBL) producers (conferring resistance to third-generation cephalosporin antibiotics), and carriage of ESBL and carbapenemase genes (conferring resistance to carbapenem antibiotics) were positively associated with transmission.
- Fourteen genetic lineages were associated with clusters in multiple neonatal units, together accounting for two-thirds of all infections.
- Many of these same lineages are common causes of drug-resistant hospital outbreaks in high-income countries.

What Do These Findings Mean?

- A substantial proportion of *K. pneumoniae* neonatal sepsis cases are potentially preventable with improvements in IPC in neonatal units.
- Further work is needed to identify and better understand transmission routes and risk factors for transmission to support the implementation of effective and scalable IPC solutions.
- Our findings highlight the importance of genomic surveillance to support IPC interventions for *K. pneumoniae* and other pathogens, and reveal many of the same ‘drug-resistant problem clones’ are responsible for hospital outbreaks across high- and low-income countries.
- The high rates of ESBL gene carriage among isolates in this study indicates that empirical treatment based on the current WHO guidelines may result in high rates of treatment failure.

- The limitations of this study include the lack of sufficient clinical data to allow high-resolution investigation of transmission dynamics, as well as facility-level data to investigate contributors to the observed differences in transmission burden across sites.

Introduction

Sepsis is a leading cause of death among neonates, particularly in Africa and Asia, where the highest global incidence of neonatal mortality was recorded in 2022, with over 21 deaths per 1000 live births [1–3]. Bacterial infections are the most common cause of neonatal sepsis globally, with the predominant pathogens varying across geographical regions [4–10]. In Africa and Asia, *K. pneumoniae* is the primary cause of neonatal sepsis, and displays high rates of resistance to empirical antimicrobials recommended by WHO [5,11]. This makes the infections difficult to treat which contributes to higher neonatal mortality rates, mostly in low- and middle-income countries (LMICs) where the disease burden is highest and access to high-quality medical care and effective antibiotics is often limited [12,13].

Invasive bacterial disease in neonates is associated with two main transmission routes; vertical transmission from the mother, and horizontal transmission from other sources including the hospital environment and healthcare workers [8,14,15]. As such, efforts to reduce the burden of neonatal sepsis focus on intrapartum antimicrobial prophylaxis [16], improving infection prevention and control (IPC) practices, early case identification, and sepsis management [17].

K. pneumoniae is well-established as a leading cause of nosocomial infection outbreaks in hospitals globally [18], more likely to cause clusters than *Escherichia coli* or other Gram negatives [19]. *K. pneumoniae* outbreaks in neonatal care units are well documented in the literature, including the use of pathogen whole-genome sequencing (WGS) to resolve transmission patterns and identify infection sources [20–25]. Nosocomial transmission in LMICs have been linked to poor IPC practices often resulting from limited resources, including inadequate access to water, sanitation, and hygiene, ineffective ward cleaning and sharing of beds and equipment [26–28]. In a retrospective WGS study of *K. pneumoniae* bloodstream infections over 20 years in a single hospital in Malawi, the majority (77%) of cases due to key lineages investigated (ST14, ST15, ST35, ST39) were attributable to

215 nosocomial transmission, suggesting that more effective IPC practices supported by
216 investment in IPC resources could help limit the incidence of neonatal sepsis [22].

217 To our knowledge, no study has quantified the contribution of nosocomial transmission to the
218 burden of hospital-based *K. pneumoniae* neonatal sepsis across LMICs. This information is
219 crucial to understand and contextualise the role of effective IPC measures in lowering the
220 burden of neonatal sepsis in these settings, which is increasingly important as rising AMR
221 further reduces treatment options. To address this gap, this study aimed to estimate the
222 proportion of *K. pneumoniae* neonatal sepsis infections that are attributable to nosocomial
223 transmission in neonatal care settings in LMICs in Africa and Asia.

224

225 Methods

226 Ethical considerations

227 Each contributing study obtained local ethical approval, details of ethics committees and
228 approval numbers are listed in **S1 Table**. The Baby GERMS-SA [29] and Malawi-Liverpool-
229 Wellcome (MLW) Biobank [22] studies were granted consent waivers from local ethics
230 committees for the use of routine diagnostic specimens/isolates and routine clinical data for
231 research; all other studies obtained informed consent from the parents of participating
232 neonates. Approval for the cross-study analysis presented here was granted by the
233 Observational / Interventions Research Ethics Committee of the London School of Hygiene
234 and Tropical Medicine (ref #29931). Anonymised data from each primary study were shared
235 for analysis, including date of specimen collection and hospital site identifier (where the
236 study included more than one site), along with pathogen WGS data for the corresponding
237 bacterial isolate.

238 ## Bacterial isolates and sequence analysis

239 Whole-genome sequences of *K. pneumoniae* isolated from neonates in LMICs in Asia and
240 Africa were sourced from prospective clinical studies of neonatal sepsis: Burden of Antibiotic
241 Resistance in Neonates from Developing Societies (BARNARDS) [5], Sepsis Prevention in
242 Neonates in Zambia (SPINZ) [30–32], Baby GERMS-SA [29,33], Mortality from Bacterial
243 Infections Resistant to Antibiotics (MBIRA) [34], Indian District Hospitals (DH) [35], Group B
244 Strep Correlates of Protection Study (GBS-COP) [36], Neonatal Infections & MicroBIome
245 (NIMBI-plus) [37], NeoBAC [38]; and long-term prospective surveillance of bloodstream
246 infection at Queen Elizabeth Central Hospital in Blantyre, Malawi (MLW Biobank) [22] and
247 Kilifi County Teaching and Referral Hospital (KCTRH) carried out by the Kenya Medical
248 Research Institute (KEMRI)/Wellcome Trust Research Programme (KWTRP) [38]. All
249 included studies were undertaken as observational or surveillance studies aiming to capture
250 all blood culture-positive sepsis cases during a defined period, not specifically instigated to
251 investigate or respond to outbreaks. These studies and the corresponding whole-genome
252 sequence data are a subset of those included in a meta-analysis of K and O antigen
253 prevalence amongst *K. pneumoniae* causing neonatal sepsis in LMICs published in 2026
254 [39]. That study adjusted for within-unit clustering to minimise the impact of localised
255 transmission events on the estimation of regional antigen prevalence, but did not investigate
256 transmission as a phenomenon, which is the goal of the present study. Details of samples
257 included from each study are given in **Table 1**, and characteristics of each study site are
258 given in **Table 2** (this represents information provided by co-authors from each study team).
259 We used the United Nations Statistics Division M49 standard to assign countries to
260 geographical sub-regions (Asian countries) and intermediate regions (African countries) [40].
261

262 **Table 1. Summary of isolates included in the study**

Region	Country	Study [Ref]	Site no.	No. *Kpn* genomes	No. sepsis isolates	Year of study	Temporal span (weeks)
Eastern Africa	***All***	-	-	**1124**	-	-	-
	Ethiopia	BARNARDS [5]	Site 1	94	443	2017	39
		MBIRA [34]	Site 2	31	n/a	2021	30
	Kenya	KWTRP [38]	Site 3	167	689	2013 - 2023	537
		NeoBAC [38]	Site 4	46	77	2021 - 2022	40
		NeoBAC [38]	Site 5	20	83	2021 - 2022	60
	Malawi	MBIRA [34]	Site 6A	27	n/a	2020 - 2021	55
		MLW [22]	Site 6B	362	n/a	2013 - 2020	377
	Rwanda	BARNARDS [5]	Site 7	15	240	2016 - 2017	79
	Tanzania	MBIRA [34]	Site 8	58	n/a	2021	39
	Zambia	MBIRA [34]	Site 9	19	n/a	2021	36
		SPINZ [30–32]	Site 10	285	424	2015 - 2017	72
Western Africa	***All***	-	-	**75**	-	-	-
	Ghana	MBIRA [34]	Site 11	25	n/a	2020 - 2021	45
	Nigeria	BARNARDS [5]	Site 12	34	228	2016 - 2017	96
		BARNARDS [5]	Site 13	16	315	2017	41
Southern Africa	***All***	-	-	**243**	-	-	-
	Botswana	NIMBI-plus [37]	Site 14	29	96	2022 - 2023	74
	South Africa	BARNARDS [5]	Site 15A	12	94	2016 - 2017	77
		Baby GERMS-SA [29,33]	Site 16	34	190	2019 - 2020	51
		Baby GERMS-SA [29,33]	Site 17	27	93	2019 - 2020	45
		Baby GERMS-SA [29,33]	Site 18	23	143	2019 - 2020	47
		Baby GERMS-SA [29,33]	Site 19	22	116	2019 - 2020	47
		Baby GERMS-SA [29,33]	Site 20	21	237	2019 - 2020	49
		Baby GERMS-SA [29,33]	Site 21	13	128	2019 - 2020	34
		GBS-COP [36]	Site 22	49	70	2019 - 2020	69
		MBIRA [34]	Site 15B	13	172	2021	25
South Asia	***All***	-	-	**81**	-	-	-
	Bangladesh	BARNARDS [5]	Site 23	17	192	2016 - 2017	89
	India	DH [35]	Site 24	34	141	2019 - 2022	116
	Pakistan	BARNARDS [5]	Site 25	30	767	2016 - 2017	81
Total	-	-	-	**1523**	-	-	-

263 Sites 6A and 6B represent the same neonatal unit that was included in two separate study protocols spanning
264 different time periods as shown; data from these studies were treated separately in the analysis, as sample
265 collection and WGS protocols were conducted separately. Similarly, sites 15A and 15B represent the same
266 neonatal unit that was included in two distinct studies. The “No. sepsis isolates” column shows the total number
267 of culture-positive (regardless of pathogen) blood/cerebrospinal fluid samples from neonates in each site during
268 the respective sampling periods. *Kpn* – *Klebsiella pneumoniae*, n/a – not available.

269 **Table 2. Characteristics of facilities included in the study**

Region	Country	Location	Facility size	No. neonatal beds	Piped water available	Onsite neonatal surgical facilities	Site
Eastern Africa	Ethiopia	Urban	Very Large	30	Sometimes	Yes	Site 1
		Urban	Medium	40	Sometimes	Yes	Site 2
	Kenya	Rural	Large	75	Always	Yes	Site 3
		Urban	Large	100	Always	No	Site 4
		Urban	Large	90	Always	No	Site 5
	Malawi	Urban	Very Large	70	Mostly	Yes	Site 6A/6B
	Rwanda	Rural	Medium	15	Always	Yes	Site 7
	Tanzania	Urban	Very Large	100	Always	Yes	Site 8
	Zambia	Urban	Large	57	Mostly	Yes	Site 9
		Urban	Very Large	60	Sometimes	Yes	Site 10
Western Africa	Ghana	Urban	Very Large	55	Always	Yes	Site 11
	Nigeria	Urban	Very Large	30	Mostly	Yes	Site 12
		Urban	Large	20	Always	Yes	Site 13
Southern Africa	Botswana	Urban	Large	36	Mostly	Yes	Site 14
	South Africa	Urban	Very Large	132	Always	Yes	Site 15A/15B
		Urban	Very Large	71	Always	Yes	Site 16
		Urban	Large	36	Always	Yes	Site 17
		Urban	Large	72	Always	Yes	Site 18
		Urban	Large	45	Always	Yes	Site 19
		Urban	Large	60	Always	Yes	Site 20
		Urban	Large	92	Always	Yes	Site 21
		Urban	Very Large	200	Always	Yes	Site 22
South Asia	Bangladesh	Urban	Very Large	80	Mostly	Yes	Site 23
	India	Urban	Small	12	Always	No	Site 24
	Pakistan	Urban	Large	30	Always	Yes	Site 25

270 Facility size (total number of beds) – Small: 50–150 beds, Medium: 151–300 beds, Large: 301–600 beds, Very
271 Large: >600 beds
272

273

274

275 For the prospective studies (BARNARDS, SPINZ, Baby GERMS-SA, MBIRA, DH, GBS-
276 COP, NIMBI-plus, NeoBAC), blood culture was performed for all neonates with clinically
277 suspected sepsis, and all blood culture isolates identified as *Klebsiella* that could be later
278 revived for DNA extraction were included in sequencing and this analysis. Baby GERMS-SA,
279 GBS-COP, KWTRP, and MLW also included *Klebsiella* cultured from cerebrospinal fluid
280 (CSF) of participants. For the long-term prospective surveillance studies (KWTRP, MLW),
281 isolates from all positive blood or CSF cultures were stored for future research. At KWTRP,
282 all neonates had blood culture on admission and again if their clinical condition deteriorated.
283 At MLW, cultures were performed for all neonates with clinical signs of sepsis or meningitis,
284 temperature >37.5°C, or other signs of clinical deterioration.

285 For all studies, neonatal isolates identified as *Klebsiella*, which could later be revived for
286 DNA extraction, were sequenced and those sequences that passed quality filters were
287 included in this analysis (see inclusion criteria below). Details of microbiology, sequencing,
288 and bioinformatics methods used in each study, including the quality-control criteria applied
289 prior to sharing genome sequences for this analysis, have been reported previously [39] and
290 are summarized in **S2 Table**. Briefly, all studies utilized Illumina platforms and assembled
291 genomes using either SKESA v2.3.0 (MBIRA) or SPAdes (all other studies). Genome
292 assemblies were analysed using Kleborate v3.0 [41] to confirm species, identify multi-locus
293 sequence types (STs), antimicrobial resistance (AMR) and hypervirulence determinants, and
294 to identify capsular (K) loci (KL) and O types using Kaptive v3.0 [42].

295 ## Inclusion and exclusion criteria

296 Inclusion criteria for individual samples from the studies were: *K. pneumoniae* isolated from
297 the blood or CSF of a neonate (defined as 0-28 days post birth), between 2013 and 2023
298 inclusive. CSF isolates were included from three studies (KWTRP surveillance, n=5; GBS-
299 COP, n=2; MLW Biobank, n=31). Repeat *K. pneumoniae* isolates from the same participant
300 with the same KL were excluded, ensuring that each genome represents a unique infection

301 from an individual neonate (with the exception of MLW Biobank, for which archived isolates
302 were not associated with patient identifiers thus precluding the exclusion of repeat isolates).
303 Genome sequences identified as species other than *K. pneumoniae* or failing to meet the
304 quality control criteria for assemblies (≤1,000 contigs and genome size 5–6.2 Mbp, as
305 reported by Kleborate v3) were excluded. Additionally, study sites contributing fewer than 10
306 high-quality *K. pneumoniae* genomes that met the inclusion criteria were excluded (54
307 genomes from 12 sites), as it is not meaningful to estimate a fraction when the denominator
308 is <10. Specifically, data were excluded from twelve sites that participated in multicenter
309 studies (MBIRA, BARNARDS, DH, GBS) but yielded fewer than 10 high-quality *K.*
310 *pneumoniae* genomes. Seven of these sites had <5 high-quality *K. pneumoniae* genomes
311 each (no clusters as per the definition below); five sites had n=6-8 isolates each, 3 of which
312 had a cluster. The reasons for low counts vary but are likely associated with differences in
313 patient numbers as well as diagnostic stewardship and sensitivity. A flow diagram detailing
314 sample inclusion is shown in **S1 Figure**, including available information on the number of
315 samples that were not stored, could not be revived for DNA extraction, failed sequencing, or
316 did not meet genome quality control thresholds for each contributing study.

317 **Identification of transmission clusters**

318 Pairwise single nucleotide variant (SNV) distances were calculated using Pathogenwatch,
319 which enumerates differences in a library of 1,972 core genes (totalling 2,172,367 bp) [43].
320 Transmission clusters were defined within each study site based on both the pairwise
321 genetic distances (≤10 SNVs) and temporal distances (≤4 weeks based on date of specimen
322 collection) between isolates. The igraph v1.4.1 R package [44] was used to identify single-
323 linkage transmission clusters by constructing an undirected graph from an edge list of isolate
324 pairs. Each edge in the undirected graph represented a pairwise connection between
325 isolates that were genetically similar (pairwise distance less than or equal to the specified
326 genetic distance threshold), sampled within a specified temporal window (up to the specified

327 temporal distance threshold), and isolated from the same site. Distinct transmission clusters
328 were then defined as connected components of the resulting graph. This results in single-
329 linkage clusters, where each isolate is within the thresholds of both genetic and temporal
330 distance from at least one other isolate in the cluster, but pairs of isolates within the same
331 cluster may be separated by distances greater than the threshold. Therefore clusters can
332 include isolates cultured over any period, as long as the distances between consecutive
333 isolates in the cluster fall below the temporal threshold.

334 Estimation of cluster and transmission proportions

335 We estimated two key parameters – cluster proportion and transmission proportion – as
336 indices of the contribution of transmission to the burden of *K. pneumoniae* neonatal disease
337 in each neonatal care setting. The cluster proportion estimate was calculated as the number
338 of *K. pneumoniae* isolates in clusters, divided by the total number of culture-confirmed and
339 sequenced *K. pneumoniae*, for each site. The transmission proportion, on the other hand,
340 was a conservative estimate of the proportion of *K. pneumoniae* isolates that were
341 attributable to transmission. To estimate this, we excluded the first neonate in each cluster
342 as a potential index patient, and assumed that all other infections within clusters were due to
343 onward transmission in the unit. This almost certainly results in an underestimation of
344 infections attributable to transmission, as the index patient may have also acquired *K.*
345 *pneumoniae* from a contaminated source within the unit or an asymptomatically colonised
346 neonate. The transmission proportion estimate was thus calculated as below:

347 $$\frac{(total\ number\ of\ cluster\ isolates) - (number\ of\ index\ cases)}{total\ number\ of\ isolates}.$$

348 Sensitivity analyses

349 We conducted a sensitivity analysis to determine the impact of the choice of genetic distance
350 and temporal distance thresholds on the estimates of cluster proportion and transmission
351 proportion. The estimates were calculated and compared across a range of genetic distance

352 thresholds (range: 0–25 SNVs) and temporal distance thresholds (range: 1–52 weeks). We
353 also assessed how using different methods for calculating pairwise genetic distances
354 between all isolate pairs could impact the obtained estimates. To do this, we generated
355 reference-free SNV alignments of all genomes in the BARNARDS and SPINZ datasets using
356 the split k-mer analysis (SKA) method with SKA2 v0.4.1 [45,46]. A SKA index was first built
357 from the input assemblies using a k-mer size of 31, after which pairwise distances between
358 all genomes were calculated using the "distance" subcommand with a minimum frequency
359 threshold of 0.9 to include only core-genome SNVs. The cluster and transmission proportion
360 estimates were re-calculated using these SKA-derived SNV distances and compared to
361 those obtained using the Pathogenwatch core gene SNV distances.

362 Statistical analysis

363 All analyses and visualisations were performed using R v4.2.3 [47].

364 The methods for clustering infections, quantifying transmission, and exploring the sensitivity
365 of the estimates to selected thresholds (as described above) are implemented in a species-
366 agnostic Shiny web application (https://klebsiella.shinyapps.io/transmission_estimator/), with
367 source code available at https://github.com/klebgenomics/transmission_estimator (DOI:
368 10.5281/zenodo.17593948).

369 To assess heterogeneity of estimates between sites, for the multicentre studies BARNARDS
370 and MBIRA, we performed meta-analysis of proportions using a generalised linear mixed
371 model (GLMM) with a logit transformation to pool estimates of cluster proportion and
372 transmission proportion across all study sites. A random effects model was applied to
373 account for between-site variability, and 95% confidence intervals were computed using the
374 Clopper-Pearson method. Heterogeneity between sites was assessed visually using Forest
375 plots and quantitatively using the I^2 statistic. The meta-analysis was conducted using the
376 metaprop function of the meta v7.0.0 R package [48].

377 To identify facility characteristics associated with transmission, we performed pairwise two-
378 tailed binomial tests with Bonferroni correction, with facility-level data as categorical (facility
379 size, number of neonatal beds, availability of piped water) or binary (onsite availability of
380 neonatal surgical facilities) variables.

381 The proportions of isolates with extended-spectrum beta-lactamase (ESBL) and
382 carbapenemase genes were compared between clustered and non-clustered cases using
383 the Chi-squared test. To model different bacterial features (ESBL gene carriage,
384 carbapenemase gene carriage, ST, O type, K locus) and institutional factors (hospital site)
385 as potential predictors of transmission, we fitted logistic regression models in which each
386 introduction was treated as a single observation, with the outcome recorded as transmission
387 (cluster size ≥2) or no evidence of transmission (unclustered singleton case). For each
388 cluster, each predictor was assigned the consensus value for that cluster (e.g. if 3 of 4 cases
389 had ESBL gene/s detected, the cluster was recorded as ESBL-positive). Presence of ESBL
390 (Kleborate score ≥1) or carbapenemase (Kleborate score ≥2) genes were encoded as binary
391 variables. ST was encoded as a categorical variable, with one category per ST for commonly
392 transmitted STs (occurring in ≥3 clusters and ≥2 sites), and the reference category being the
393 group of all 158 'other STs' (49.2% in the reference category). O type was encoded as a
394 categorical variable, with the most common type, O1 (51.6%), as the reference category. K
395 locus was encoded as a categorical variable, with the top 10 K loci compared against 'other
396 K loci' as the reference category (n=70, 87.5% in the reference category). Models were fitted
397 using Firth's bias reduction method, implemented in the logistf package in R (v1.26.0). All
398 alternative models were compared using the likelihood ratio test, using the anova function in
399 base R.

400

401 ### Data availability

402 Sample-level data are described in **S3 Table** (dates are shown as year only, to protect
403 participant privacy). Raw whole-genome sequence data were deposited by the originating
404 study teams in INSDC databases, under the following BioProjects: BARNARDS,
405 PRJEB33565; SPINZ, PRJEB46513; MLW, PRJEB42462; NIMBI-plus, PRJNA1168993; DH,
406 PRJEB70311; Baby GERMS-SA, PRJNA796486 and PRJNA1282934; GBS-COP,
407 PRJNA1175467; KWTRP, PRJNA1265413; MBIRA: PRJNA1274034, NeoBAC,
408 PRJNA1265413. All input data and code required to reproduce the results, figures, and
409 tables presented in this paper are available at
410 https://github.com/klebgenomics/KlebNNS_transmission (DOI: 10.5281/zenodo.17591910).
411 This study is reported as per the Strengthening the Reporting of Observational Studies in
412 Epidemiology (STROBE) guideline (**S1 Checklist**).

413

414 # Results

415 ### Estimating transmission proportion

416 The study included 1,523 isolates from 27 sites in 13 countries, including Malawi (n=389),
417 Zambia (n=304), Kenya (n=233), Ethiopia (n=125), Tanzania (n=58) and Rwanda (n=15) in
418 Eastern Africa; Nigeria (n=50) and Ghana (n=25) in Western Africa; South Africa (n=214)
419 and Botswana (n=29) in Southern Africa; India (n=34), Pakistan (n=30) and Bangladesh
420 (n=17) in South Asia (**Table 1, S2 Figure**). Sample size per site ranged from 12 to 362
421 genomes, with dates of isolation spanning 26 to 537 weeks per site. Six sites included data
422 from only one year. A majority of the isolates were from Eastern Africa (n=1124), followed by
423 Southern Africa (n=243), South Asia (n=81), and Western Africa (n=75). See **Table 2** for
424 characteristics of neonatal care facilities included in the study.

425 A total of 156 transmission clusters were identified across all sites, comprising 1,035 unique
426 infections (68.0%) (**S3 Figure**). The identified clusters spanned between 1 and 249 days
427 duration between the first and last cases (median: 14 days; interquartile range [IQR]: 6–28
428 days), with a median of 3 infections per cluster (range: 2–188, IQR: 2–5) (**S4 Table)**. Almost
429 half (73/156) of the clusters comprised only 2 infections. Excluding these 73 clusters as
430 potential coincidental isolation of similar but independently introduced strains rather than
431 nosocomial transmission, there were still 879 (57.7%) infections involved in 83 clusters
432 affecting at least 3 patients each (median cluster size, 5 cases). Sixteen clusters overlapped
433 either the beginning (n=7, cluster size: median = 3, range = 2–188) or the end (n=9, cluster
434 size: median = 3, range = 2–32) of the sampling periods in the respective sites, suggesting
435 that transmission may have been ongoing before sampling began or continued after
436 sampling ended.

437 The median estimates, across 27 sites, for cluster and transmission proportion were 53.3%
438 and 33.5%, respectively (**Figure 1**). Sensitivity analyses showed these estimates were
439 robust to the choice of thresholds and genetic distance estimation methods (**S4 Figure, S1**
440 **Appendix**). Cluster and transmission proportion estimates varied widely by site, ranging
441 from 0 to 93% and 0 to 87%, respectively (**Figure 1**). In 10 of the 27 sites (37%), at least half
442 of all infections were attributable to transmission, and in 14 sites (52%) at least a third of
443 cases were attributable to transmission. Across all sites, the median number of clusters
444 detected per site per year was three (IQR: 2–4, range: 0–13). Considering only clusters with
445 ≥3 patients, we identified median one cluster per site per year (IQR: 1–3, range: 0–8).
446 Transmission proportions were heterogeneous within regions, although higher values were
447 estimated in Eastern Africa (median=65.0% [range: 29.6–93.5%], n=11 sites) compared with
448 Western Africa (40% [37.5–41.2%], n=3 sites) and South Asia (43.3% [23.5–88.2%], n=3
449 sites). Intermediate values were estimated in Southern Africa (median = 54.8% [0–77.3%],
450 n=10 sites).

451



Figure 1. Estimates of cluster and transmission proportion across sites.
(A) Cluster proportion **(B)** Transmission proportion. Plots show the point estimates (boxes) and 95% confidence intervals (horizontal bars) for each site. The median estimate is represented by the broken vertical line.

461 To determine whether differences in study design and sampling methodology contributed to
462 the heterogeneity observed between sites, we conducted two secondary meta-analyses
463 using data from two multi-site studies in our dataset (MBIRA and BARNARDS), each of
464 which used a consistent study protocol across multiple sites [5,34]. The pooled estimate of
465 transmission proportion across the seven BARNARDS sites was 26.1% (95% CI: 11.5–
466 49.0%, range: 0–79%) and there was substantial heterogeneity between sites (I^2 = 88.6%
467 [79.0%–93.8%]). The findings with the MBIRA dataset were similar, with a pooled
468 transmission proportion estimate of 37.0% (95% CI: 15.8–64.8%, range: 8–86%) and
469 significant heterogeneity (I^2 = 89.0% [78.8–94.3%] was observed across the six sites.
470 Notably, the lowest cluster proportion observed in both these studies was at the same
471 neonatal unit, sampled under different protocols at different time periods (BARNARDS 15A,
472 2016-2017 and MBIRA 15B, 2021), but yielding similar results each time (0 clusters out of 12
473 isolates, and 1 clustered pair out of 13 isolates, respectively). This suggests that the
474 observed heterogeneity in the full analysis is unlikely to be influenced by primary study
475 protocol differences alone, but may instead reflect variation in unmeasured factors such as
476 demographic, geographic and/or site-specific variations.

477 **S5 Figure** shows a comparison of cluster proportion across different sites based on
478 descriptive characteristics of the health facilities (summarised in **Table 2**). Notably facility
479 size and neonatal bed count were not associated with the number of *K. pneumoniae* isolates
480 per site (R^2 <0.01, p=0.993 and R^2 = 0.14, p=0.053, respectively using linear regression).
481 For example, the lowest cluster proportions were observed at site 15, which is one of the
482 largest neonatal units but as noted above had very few cases or clusters, potentially
483 because it is one of the better-resourced facilities (located in Cape Town, South Africa with
484 relatively strong microbiological diagnostics, surveillance and IPC capacity). Facilities with
485 only occasional availability of piped water (two in Ethiopia, one in Zambia) had a higher
486 proportion of cases in clusters (87.7% [range: 64.5–89.4%]) than those where piped water
487 was reported as being available most of the time (n=6; 42.5% [23.5–74.0%]; p<0.001 using

488 Binomial test) or always (n=18; 52.9% [0–93.5%]; p<0.001 using Binomial test) (**S5 Figure**).
489 District hospitals with no surgical facilities onsite (two in Kenya, one in India) also had a
490 higher proportion of cases in clusters (88.2% [65.0–93.5%]) than hospitals with surgical
491 facilities available onsite (n=24, 49.9% [0–89.4%], p<0.001 using Binomial test).

492 **Genomic characteristics of transmitted *K. pneumoniae***

493 A total of 172 distinct *K. pneumoniae* STs were identified amongst the included isolates (**S5**
494 **Table**). Of these, 57 STs were associated with at least one transmission cluster. We defined
495 commonly transmitted STs as those that were identified in ≥3 transmission clusters in two or
496 more sites. Fourteen STs met this definition (**Figure 2**), and these made up 63.8%
497 (n=972/1523) of all infections, including 71.8% (n=743/1035) of clustered infections and
498 46.9% (n=229/488) of unclustered infections. Twelve of the 14 commonly transmitted STs
499 were detected in ≥3 countries each, however ST152 and ST25 were each identified in just
500 one country (South Africa and Malawi, respectively). Most of the 14 STs were associated
501 with clusters at Malawi site 6B (see **Figure 2B**), which is not unexpected given this is the
502 largest dataset and originates from seven years of routine blood culture surveillance;
503 however, besides ST25, all common STs associated with clusters at this site were also
504 associated with clusters at multiple other sites. The 14 commonly transmitted STs were
505 responsible for most large clusters with ≥15 cases (n=6/10 clusters; 60%; **Figure 2D**),
506 although four large clusters were caused by rarely transmitting STs (ST6775, n=29; ST37,
507 n=26; ST2004, n=20; and ST1414, n=17). **Figure 3** shows, for each ST, the number of
508 unique introductions (treating each cluster or singleton as a unique strain 'introduction' in a
509 neonatal ward) vs the number of infection clusters. Across all STs, the mean fraction of
510 introductions resulting in detected infection clusters was 15.3%, and this fraction was
511 significantly higher among the 14 commonly transmitted STs compared to the other 158 STs
512 (mean 33.1% vs 13.8%, Chi-squared test p<0.001).

513



	Clusters	Single	Sites	Sites (clusters)	aOR [95% CI]	*P*
ST17	17	32	18	10	2.2 [1.1-4.5]	**0.030**
ST307	15	43	13	8	1.4 [0.7-2.7]	0.41
ST14	13	29	10	6	1.8 [0.8-3.9]	0.13
ST39	10	31	18	7	1.2 [0.6-2.7]	0.63
ST45	8	11	10	6	2.4 [0.9-6.4]	0.10
ST35	5	5	3	2	2.2 [0.6-8.5]	0.24
ST101	5	12	7	4	2.0 [0.7-6.1]	0.22
ST1741	4	2	3	3	20.9 [1.2-363.7]	**0.013**
ST29	4	9	7	4	2.6 [0.7-8.9]	0.16
ST48	4	9	7	3	1.6 [0.5-5.5]	0.46
ST607	4	11	7	3	1.4 [0.4-4.2]	0.62
ST15	3	17	11	3	0.7 [0.2-2.7]	0.65
ST152	3	5	7	3	3.0 [0.7-12.8]	0.16
ST25	3	13	7	2	1.0 [0.3-3.5]	0.99

Figure 2. Commonly transmitted *K. pneumoniae* STs.
(A) Transmission profile showing number of clusters, number of singleton cases, total number of sites the STs were detected, number of sites where the STs were part of transmission clusters, their adjusted odds ratios compared to other STs in a logistic regression model to assess association with transmission, and corresponding p-values (columns from left to right). P-values for STs with a significant association with transmission are formatted in bold (see Methods for details of the logistic regression analysis). **(B)** Site distribution of cluster isolates. Points are coloured to indicate geographical region and sized to indicate number of clustered isolates per site. **(C)** Resistance distribution (proportion) of cluster isolates. Resistance scores are as reported by Kleborate based on the presence or absence of extended-spectrum beta-lactamase genes (ESBL), carbapenemase genes (Carb), and/or colistin resistance determinants (Col). **(D)** ST composition of large clusters. Points are coloured to indicate the 14 commonly transmitted STs and sized to indicate the number of isolates, as per the figure legend.



Figure 3. Transmission probability of individual STs
(A) Distribution of the fraction of strain introductions resulting in clusters, for individual STs. Bars are coloured to indicate commonly transmitted STs (per the panel legend), defined as STs that were identified in ≥3 transmission clusters in two or more sites. **(B)** Number of unique introductions vs number of clusters, for individual STs. Points are sized to indicate the number of sites where clustered isolates were detected for each ST, and coloured to indicate commonly transmitted STs significantly associated with transmission in the logistic regression model. The dashed line shows y=x, along which the number of unique introductions is equal to the number of clusters. The solid line represents a linear regression line of best fit through the origin (slope 0.28, R^2=0.920). **(C)** Fraction of clusters and singletons with ESBL and/or carbapenemase. Points are plotted for the 57 STs involved in clusters, and coloured to indicate commonly transmitted STs significantly associated with transmission. ST: sequence type. ESBL/CP: extended-spectrum beta-lacatamase or carbapenemase gene carriage (Kleborate resistance score ≥ 1).

The majority of isolates (n=1384/1523, 90.9%) carried an ESBL or carbapenemase gene. Clusters were more likely to carry ESBL (94.2% of clusters (n=147/156) vs 81.8% of singletons (n=399/488), p<0.001) or carbapenemase genes (19.9% of clusters (n=31/156) vs 10.2% of singletons (n=50/488), p=0.0025) (**S6 Table**). In a logistic regression model for transmission, treating each cluster or singleton as a unique strain 'introduction' in a neonatal ward, and defining the outcome for each introduction as either evidence of transmission (i.e.

551 cluster of size ≥2) or no evidence of transmission (i.e. a singleton unclustered case),
552 transmission was significantly positively associated with carriage of ESBL genes (adjusted
553 odds ratio, aOR = 2.84 [95% CI: 1.45–5.57], p<0.001) or carbapenemase genes (aOR =
554 1.81 [95% CI: 1.10–2.98], p=0.02) (**S7 Table**). Including Site as a covariate improved model
555 fit (p=0.05 using likelihood ratio test), but did not substantially alter the effect estimates for
556 ESBLs (aOR = 2.48 [95% CI: 1.26–4.90], p=0.006) or carbapenemases (aOR = 2.08 [95%
557 CI: 1.04–4.14], p=0.04).

558 It is challenging to tease apart the effect of AMR from the effect of lineage, as certain
559 lineages may appear more likely to cause detectable infection clusters due to their
560 resistance genes (if AMR is a driver of transmission and/or infection), or strains with
561 resistance genes might appear more likely to cause detectable infection clusters due to their
562 association with particular genetic lineages (if non-AMR-related lineage-associated
563 differences drive transmission and/or infection). The 14 commonly transmitted STs showed a
564 significantly higher rate of ESBL gene carriage (amongst singleton infections or deduplicated
565 clusters) compared to the other 158 STs (94.2% (n=308/327) vs 75.1% (n=238/317),
566 p<0.0001), although there was no significant difference in carbapenemase gene carriage
567 rates (14.1% (n=46/327) vs 11% (n=35/317), p=0.30) (**S8 Table**). Amongst the 14 most
568 common transmission STs, nearly all (n=728/743; 98%) of the clustered isolates carried at
569 least one ESBL or carbapenemase gene, compared with 93% (n=213/229) amongst
570 singleton isolates of these STs (**Figure 3C**). Adding ST (as a categorical variable with each
571 of the 14 common STs as unique categories, compared to all other STs as the reference
572 category) to the logistic regression model with ESBL, carbapenemase and Site did not
573 improve the model (p=0.226), and had little impact on the estimated effects of ESBL (aOR =
574 2.16 [95% CI: 1.08–4.32], p=0.03) and carbapenemase (aOR = 2.03 [95% CI: 1.01–4.08],
575 p=0.05), and only two STs were significantly independently associated with transmission
576 (ST17, aOR = 2.24 [95% CI: 1.11–4.52], p=0.03 and ST1741, aOR = 20.9 [95% CI: 1.2–
577 363.7], p=0.01).

578

579 As K and O antigens have been proposed as potential vaccine targets, we explored their
580 prevalence (based on genomic predictions) and association with transmission in our dataset.
581 Six unique O serogroups were predicted (see **S9 Table**), the majority being O1 (n=332/644,
582 51.6%) or O2 (n=158/644, 24.5%), which were common amongst both clusters and
583 singletons (51.3% vs 51.6%, respectively for O1, 26.9% vs 23.8% for O2). Including O types
584 in the transmission model with ESBL and carbapenemase genes, with or without ST and/or
585 Site, did not improve model fit (p>0.2 using likelihood ratio test), and no O types were
586 significant in any models (see **S7 Table**).

587

588 Eighty distinct K loci were detected. Forty-three K loci were found in isolates associated with
589 transmission clusters, and 39 of these were also identified in singleton isolates (**S10 Table**).
590 Distinct K loci were associated with specific STs, making it difficult to tease apart the effect
591 of K antigens from strain background. For example, KL102, which was the most common K
592 locus associated with transmission, was closely associated with ST307: 95% (n=241/253) of
593 KL102 isolates from transmission clusters were ST307, and ST307 accounted for 83%
594 (n=15/18) of KL102 clusters detected. Similarly, 79% (n=42/53) of KL25 cluster isolates
595 belonged to either ST17 (n=33, 62%) or ST607 (n=9, 17%). Including the top 10 most
596 common K loci in the transmission model together with ESBL and carbapenemase genes,
597 with or without ST and/or Site, did not improve the model fit (p>0.38 using likelihood ratio
598 test), although KL62 was significantly positively associated with transmission (aOR 4.77
599 [95% CI, 1.30–17.49], p=0.025) in the model with ESBL and carbapenemase genes, ST, and
600 Site. KL62 was associated with 12 clusters (n=26 isolates) out of 34 introductions (n=6
601 different STs) across 16 sites.

Discussion

Neonatal sepsis caused by *K. pneumoniae* infection is a significant health challenge in Africa and Asia with disproportionately high incidence and mortality rates. Our analysis estimated that over half of all neonatal sepsis cases at the included sites were within transmission clusters, with a median 33.5% of all cases attributable to nosocomial transmission (**Figure 1**).

Transmission analyses typically require detailed data on patient admission, ward movements, and recent healthcare exposures in addition to pathogen sequence data; these are hard to standardise across studies and thus between-study comparisons or meta-analyses are challenging. Here, however, we used studies in which all consecutive neonates with sepsis in a defined physical unit were sampled and the resulting isolates sequenced, allowing us to undertake a standardised clustering analysis based on genetic and temporal distances within each unit, applied to data collected across 10 unique studies.

Furthermore, as our goal was to estimate the fraction of cases linked to others in transmission clusters, rather than trying to resolve specific transmission chains or pathways, our approach was robust to changes in distance thresholds (see **S4 Figure, S1 Appendix**). This is because lowering clustering thresholds tends to break larger single-linkage clusters into smaller ones (which has no impact on the overall fraction included in clusters), rather than breaking clusters into completely un-linked singleton cases. Variations in genetic and temporal distance thresholds have a greater impact in real-time outbreak investigations, where the goal is to identify specific transmission events and sources. In that context, the choice of thresholds can be adjusted to achieve a desired preference for sensitivity or specificity in cluster detection. Interestingly, previous studies have proposed whole-genome SNV cutoffs of between 21 and 25 for identifying *K. pneumoniae* nosocomial transmission, which is equivalent to the 10 Pathogenwatch core-gene SNV threshold used in our analysis [18,49,50].

628 As with other opportunistic pathogens frequently implicated in hospital-acquired infections,
629 reservoirs and transmission routes for *K. pneumoniae* infection are abundant in the hospital
630 environment, and genomics has been used to resolve specific sources in several studies.
631 These include transmission through direct contact with contaminated surfaces, sinks,
632 cleaning supplies, medical devices, and healthcare personnel [51–55]. Neonates are at high
633 risk of hospital-acquired infections due to their naive or compromised immune systems,
634 exposure through invasive procedures in critical care settings, repeated handling by multiple
635 caregivers, and long hospital admissions [56,57]. While our study indicates a high impact of
636 IPC deficiencies in neonatal units in LMICs, identifying suitable solutions will require better
637 understanding of risk factors, transmission routes, and sources of contamination. The
638 solutions will also require appropriate testing in clinical trials or complex interventions and
639 subsequently funding for implementation at scale.

640 We observed a high diversity of *K. pneumoniae* lineages (172 unique STs) implicated in
641 neonatal sepsis cases across hospitals in Asia and Africa (**S5 Table**), consistent with
642 previous reports of a highly diverse etiology of *K. pneumoniae*-associated neonatal sepsis
643 [5,22]. A third of these STs were part of at least one transmission cluster, among which 14
644 STs were identified as commonly transmitted, occurring in ≥3 clusters and ≥2 sites.
645 However, most of these were also common among singleton isolates and accordingly our
646 logistic regression analysis indicated only two of these STs were significantly associated with
647 transmission clusters, compared with other STs. This finding is consistent with the
648 hypothesis that many different STs can become common causes of transmission clusters,
649 either because they possess traits that render them particularly fit for transmission in the
650 hospital setting, or simply because they are more prevalent (e.g. as gut colonisers in the
651 community) and therefore have greater stochastic opportunity due to more frequent
652 introductions to the hospital setting. Importantly, the signal of transmission we are exploring
653 in this study – detection as a cluster of clinical infections – is the product of multiple factors
654 including colonisation potential, virulence, and environmental survival, and we are unable to

655 tease apart the relative contributions of these different factors in determining which strains
656 are identified frequently in clusters. Notably, many of the 14 commonly transmitted STs
657 identified here, including ST11, ST14, ST15, ST17, ST29, ST101 and ST307 are recognised
658 high-risk clones, widely implicated in multidrug-resistant (MDR) hospital-acquired infections
659 worldwide [58–60], consistent with our observations. ST39 has been reported less
660 frequently, but is also disseminating rapidly worldwide, including in Africa, where it has been
661 implicated in MDR neonatal outbreaks in The Gambia and Malawi [22,28,61].

662 The overall high rates of AMR among the *K. pneumoniae* isolates (clustered and singleton)
663 in this study (see **S6 Table**) is concerning, as a high degree of resistance is known to be
664 associated with higher rates of nosocomial spread [18,62], a finding that was corroborated in
665 our analysis. We found that cluster cases had significantly higher rates of ESBL and
666 carbapenemase gene carriage compared to single cases, and isolates belonging to the 14
667 most commonly transmitted STs more frequently carried ESBL genes compared to other
668 STs (**S6 Table, S8 Table**). Carbapenemase and ESBL gene carriage were also
669 independently associated with transmission in the multivariable regression analysis (**S7**
670 **Table**). It is likely that these AMR phenotypes also contribute to case detection, as strains
671 resistant to empirical therapy are more likely to be present in the blood at sufficient quantities
672 to be detected by blood culture, making it more likely for transmitted AMR strains to result in
673 cluster detection than transmitted susceptible strains.

674 While AMR almost certainly plays a role in the successful persistence of *K. pneumoniae*
675 clones within the hospital setting, other potential factors such as survival on environmental
676 surfaces and colonisation ability are less well characterised [63]. For instance, ST17, the
677 most commonly transmitted ST in this study, was recently demonstrated to colonise the
678 gastrointestinal tracts of children for up to 2 years, a factor that may contribute to its
679 increased transmissibility [64]. ST307 is frequently associated with outbreaks and believed
680 to be adapted to the hospital environment where it can persist for extended periods and
681 rapidly spread among patients [25,63,65]. In this study, ST307 was responsible for the

682 largest identified cluster (involving 188 neonates over a 32-week period at a hospital in
683 Zambia), and 14 other clusters across 8 sites in Kenya, Malawi, Rwanda, Zambia, South
684 Africa and Ghana. However, ST307 was also detected in 43 singleton infections, and only
685 26% (n=15/58) of detected ST307 introductions in the neonatal units were associated with
686 transmission clusters (similar to the background rate observed across 158 non-commonly
687 transmitted STs). This suggests that the frequency of ST307 among hospital outbreaks may
688 reflect a generally high prevalence (i.e., as a gut coloniser) resulting in greater opportunity, in
689 combination with or instead of a specific propensity for transmission in the hospital setting.
690 Further research is needed to determine if specific STs have enhanced risk for transmission
691 once introduced into the hospital setting, and to elucidate potential factors that contribute to
692 their success as hospital-acquired opportunistic pathogens.

693 In summary, our findings demonstrate the need to improve IPC practices in neonatal care
694 settings in LMICs, and highlight the potential benefits of genomic surveillance of *K.*
695 *pneumoniae* and other pathogens to assess IPC impacts and/or to support real-time
696 outbreak detection and investigation. Limiting horizontal transmission through improved IPC
697 measures is undoubtedly a crucial prevention strategy that could prevent a significant
698 proportion of neonatal sepsis caused by *K. pneumoniae* and other pathogens, and curb the
699 spread of AMR. Studies have shown that *K. pneumoniae* outbreaks in neonatal units can in
700 principle be effectively controlled by implementing simple IPC measures like contact
701 precautions and improved hand hygiene [21,28,31]. However, to be truly effective in
702 reducing overall disease burden, these measures need to be proactive, rather than reactive,
703 and be integrated into routine practice. The implementation of consistent and effective IPC
704 measures in resource limited settings remains challenging due to resource constraints,
705 inadequate infrastructure, limited cleaning supplies, understaffing, and limited access to
706 training [66,67]. Whilst this analysis was not suited to probing the determinants of variation in
707 transmission rates, we did find that the three facilities with limited access to piped water
708 displayed high cluster proportions, highlighting the challenges faced in some settings and

709 their impact on hygiene and patient safety. In contrast, the lowest cluster proportions and the
710 lowest isolate counts were observed in consecutive studies at the same large tertiary care
711 hospital in South Africa, which is comparatively well resourced in terms of infrastructure and
712 staffing. Simplified IPC models tailored to resource-constrained settings and focused on
713 training, improved cleaning, and hand hygiene have been proposed and demonstrated to
714 reduce the incidence of neonatal sepsis and mortality [31]. However it is clear that to be
715 effective, such measures must be supported by sustained investment in infrastructure,
716 equipment, staff and training [68]. In addition, to maximise their effectiveness, IPC
717 implementation should be periodically assessed using suitable assessment tools and
718 reviewed as necessary [69–71]. IPC strategies must also be supported by expanding access
719 to blood culture facilities [72,73], accurate diagnostics and robust clinical and microbiological
720 surveillance [74], ideally incorporating whole-genome sequencing, to enable prompt
721 detection of infections, precise transmission tracking, and timely institution of control
722 measures.

723 Additionally, our findings also have implications for clinical management. WHO guidelines for
724 empirical treatment of neonatal sepsis (third-generation cephalosporins plus gentamicin [75])
725 are likely to be ineffective against the vast majority of *K. pneumoniae* characterised in this
726 study, which mostly carried ESBL genes, consistent with recent reports from NeoOBS and
727 other studies [11,76]. Access to blood culture facilities, robust clinical diagnostics and
728 susceptibility testing is essential to monitor AMR and update local syndromic guidelines, as
729 is improving access to effective antibiotics in all settings.

730 Limitations

731 The major limitation of this study is the unavailability of standardised clinical and patient-level
732 data across the included sites, which precludes a more in-depth investigation of potential
733 transmission routes and overall transmission dynamics, and the delineation of infections
734 based on the timing of disease onset relative to admission (which can be an indicator of

735 hospital- vs community-acquired infection) or to date of birth (early vs late onset sepsis).
736 Notably, component studies with sufficient data to investigate onset relative to admission
737 showed that clustered cases often had rapid onset following admission to the neonatal unit,
738 and one study linked rapid-onset disease to contaminated intravenous fluids, confirming
739 nosocomial transmission [32,37]. This suggests that the timing of symptom onset following
740 admission is not a reliable indicator of hospital- vs community-acquired disease in these
741 settings, even if such data were available. This study also did not include matched maternal
742 data to investigate vertical transmission as an alternative transmission route, albeit it is
743 important to note that studies suggest that this is unlikely to play a significant role in *K.*
744 *pneumoniae* neonatal sepsis [5,77]. Another limitation was the reliance on *post hoc*
745 collaborator-elicited facility-level data rather than systematically collected data to explore the
746 potential causes of variation in transmission rates across the different hospitals. Further
747 studies using tailored, prospectively collected data are needed to explore site-specific factors
748 that may influence transmission risk. Also, as this study predominantly comprised tertiary-
749 level healthcare facilities, our findings may not be generalisable to lower-tier healthcare
750 facilities.

751 The attributable transmission fraction observed in our analysis (median = 33.5%) is likely an
752 underestimate due to the conservative nature of our transmission proportion definition. Our
753 assumption that the 'index cases' were not attributable to transmission discounts the very
754 likely possibility that they themselves acquired their infection from the same source as the
755 subsequent cases (e.g., via contaminated equipment or the hands of a carer). The cluster
756 proportion is also likely biased towards underestimation due to missed cases (including
757 colonisation episodes that did not result in a culture-confirmed infection), excluded cases
758 (e.g., children aged >28 days in the same neonatal units), or cases that were acquired in the
759 neonatal unit but not clustered with another sequenced isolate (e.g. a contaminated source
760 may lead to colonisation or even disease in multiple neonates, of which only one individual
761 case of invasive disease is detected). Given these underestimations, even the cluster

762 proportion (median = 53.3%) probably provides a conservative estimate of the true fraction
763 of sepsis cases amenable to prevention with improved IPC measures.
764

765 Acknowledgments

766 We thank the participants and their families in all the contributing studies, and the clinical
767 and laboratory staff involved in collection and processing of relevant samples and isolates.
768 This work was supported by the MASSIVE HPC facility (www.massive.org.au). We would
769 also like to acknowledge the expert support of the sequencing and computational genomics
770 teams at the CHOP Microbiome Core (Philadelphia), International Livestock Research
771 Institute (Nairobi), Kilimanjaro Clinical Research Institute (Moshi), Neuberg Center for
772 Genomic Medicine (Ahmedabad), NICD (Johannesburg), Quadram Institute (Norwich),
773 Wellcome Centre for Human Genetics (Oxford), and Wellcome Sanger Institute
774 (Cambridge); and the BARNARDS microbiology and genomics team at Cardiff University.
775

776

References

1. World Health Organization. Newborn mortality. 2024 [cited 8 Aug 2024]. Available: https://www.who.int/news-room/fact-sheets/detail/newborn-mortality

2. Fleischmann C, Reichert F, Cassini A, Horner R, Harder T, Markwart R, et al. Global incidence and mortality of neonatal sepsis: a systematic review and meta-analysis. Arch Dis Child. 2021;106: 745–752. doi:10.1136/archdischild-2020-320217

3. Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study. The Lancet. 2020;395: 200–211. doi:10.1016/S0140-6736(19)32989-7

4. Okomo U, Akpalu ENK, Doare KL, Roca A, Cousens S, Jarde A, et al. Aetiology of invasive bacterial infection and antimicrobial resistance in neonates in sub-Saharan Africa: a systematic review and meta-analysis in line with the STROBE-NI reporting guidelines. Lancet Infect Dis. 2019;19: 1219–1234. doi:10.1016/S1473-3099(19)30414-1

5. Sands K, Carvalho MJ, Portal E, Thomson K, Dyer C, Akpulu C, et al. Characterization of antimicrobial-resistant Gram-negative bacteria that cause neonatal sepsis in seven low- and middle-income countries. Nat Microbiol. 2021;6: 512–523. doi:10.1038/s41564-021-00870-7

6. Duggan HL, Chow SSW, Austin NC, Shah PS, Lui K, Tan K, et al. Early-onset sepsis in very preterm neonates in Australia and New Zealand, 2007-2018. Arch Dis Child Fetal Neonatal Ed. 2023;108: 31–37. doi:10.1136/archdischild-2021-323243

7. Cailes B, Kortsalioudaki C, Buttery J, Pattnayak S, Greenough A, Matthes J, et al. Epidemiology of UK neonatal infections: the neonIN infection surveillance network. Arch Dis Child Fetal Neonatal Ed. 2018;103: F547–F553. doi:10.1136/archdischild-2017-313203

8. Sands K, Spiller OB, Thomson K, Portal EAR, Iregbu KC, Walsh TR. Early-Onset Neonatal Sepsis in Low- and Middle-Income Countries: Current Challenges and Future Opportunities. Infect Drug Resist. 2022;15: 933–946. doi:10.2147/IDR.S294156

9. Arvay ML, Shang N, Qazi SA, Darmstadt GL, Islam MS, Roth DE, et al. Infectious aetiologies of neonatal illness in south Asia classified using WHO definitions: a primary analysis of the ANISA study. Lancet Glob Health. 2022;10: e1289–e1297. doi:10.1016/S2214-109X(22)00244-3

10. Investigators of the Delhi Neonatal Infection Study (DeNIS) collaboration. Characterisation and antimicrobial resistance of sepsis pathogens in neonates born in tertiary care centres in Delhi, India: a cohort study. Lancet Glob Health. 2016;4: e752–e760. doi:10.1016/S2214-109X(16)30148-6

11. Russell NJ, Stöhr W, Plakkal N, Cook A, Berkley JA, Adhisivam B, et al. Patterns of antibiotic use, pathogens, and prediction of mortality in hospitalized neonates and young infants with sepsis: A global neonatal sepsis observational cohort study (NeoOBS). PLOS Med. 2023;20: e1004179. doi:10.1371/journal.pmed.1004179

12. Laxminarayan R, Matsoso P, Pant S, Brower C, Røttingen J-A, Klugman K, et al.

819 Access to effective antimicrobials: a worldwide challenge. The Lancet. 2016;387: 168–
820 175. doi:10.1016/S0140-6736(15)00474-2

821 13. Li G, Bielicki JA, Ahmed ASMNU, Islam MS, Berezin EN, Gallacci CB, et al. Towards
822 understanding global patterns of antimicrobial use and resistance in neonatal sepsis:
823 insights from the NeoAMR network. Arch Dis Child. 2020;105: 26–31.
824 doi:10.1136/archdischild-2019-316816

825 14. Hernandez-Alonso E, Bourgeois-Nicolaos N, Lepainteur M, Derouin V, Barreault S,
826 Waalkes A, et al. Contaminated Incubators: Source of a Multispecies Enterobacter
827 Outbreak of Neonatal Sepsis. Microbiol Spectr. 2022;10: e00964-22.
828 doi:10.1128/spectrum.00964-22

829 15. Frank Wolf M, Abu Shqara R, Naskovica K, Zilberfarb IA, Sgayer I, Glikman D, et al.
830 Vertical Transmission of Extended-Spectrum, Beta-Lactamase-Producing
831 Enterobacteriaceae during Preterm Delivery: A Prospective Study. Microorganisms.
832 2021;9: 506. doi:10.3390/microorganisms9030506

833 16. Kuitunen I, Kekki M, Renko M. Intrapartum azithromycin to prevent maternal and
834 neonatal sepsis and deaths: A systematic review with meta-analysis. BJOG Int J Obstet
835 Gynaecol. 2024;131: 246–255. doi:10.1111/1471-0528.17655

836 17. Dramowski A, Aucamp M, Beales E, Bekker A, Cotton MF, Fitzgerald FC, et al.
837 Healthcare-Associated Infection Prevention Interventions for Neonates in Resource-
838 Limited Settings. Front Pediatr. 2022;10: 919403. doi:10.3389/fped.2022.919403

839 18. David S, Reuter S, Harris SR, Glasner C, Feltwell T, Argimon S, et al. Epidemic of
840 carbapenem-resistant Klebsiella pneumoniae in Europe is driven by nosocomial
841 spread. Nat Microbiol. 2019;4: 1919–1929. doi:10.1038/s41564-019-0492-8

842 19. Freeman JT, Nimmo J, Gregory E, Tiong A, De Almeida M, McAuliffe GN, et al.
843 Predictors of hospital surface contamination with Extended-spectrum β-lactamase-
844 producing Escherichia coli and Klebsiella pneumoniae: patient and organism factors.
845 Antimicrob Resist Infect Control. 2014;3: 5. doi:10.1186/2047-2994-3-5

846 20. Zhang X, Li X, Wang M, Yue H, Li P, Liu Y, et al. Outbreak of NDM-1-Producing
847 Klebsiella pneumoniae Causing Neonatal Infection in a Teaching Hospital in Mainland
848 China. Antimicrob Agents Chemother. 2015;59: 4349–4351. doi:10.1128/AAC.03868-
849 14

850 21. Escobar Pérez JA, Olarte Escobar NM, Castro-Cardozo B, Valderrama Márquez IA,
851 Garzón Aguilar MI, Martinez de la Barrera L, et al. Outbreak of NDM-1-Producing
852 Klebsiella pneumoniae in a Neonatal Unit in Colombia. Antimicrob Agents Chemother.
853 2013;57: 1957–1960. doi:10.1128/aac.01447-12

854 22. Heinz E, Pearse O, Zuza A, Bilima S, Msefula C, Musicha P, et al. Longitudinal
855 analysis within one hospital in sub-Saharan Africa over 20 years reveals repeated
856 replacements of dominant clones of Klebsiella pneumoniae and stresses the
857 importance to include temporal patterns for vaccine design considerations. Genome
858 Med. 2024;16: 67. doi:10.1186/s13073-024-01342-3

859 23. Frenk S, Rakovitsky N, Temkin E, Schechner V, Cohen R, Kloyzner BS, et al.
860 Investigation of Outbreaks of Extended-Spectrum Beta-Lactamase-Producing
861 Klebsiella Pneumoniae in Three Neonatal Intensive Care Units Using Whole Genome
862 Sequencing. Antibiotics. 2020;9: 705. doi:10.3390/antibiotics9100705

24. Cornick J, Musicha P, Peno C, Seager E, Iroh Tam P-Y, Bilima S, et al. Genomic investigation of a suspected Klebsiella pneumoniae outbreak in a neonatal care unit in sub-Saharan Africa. Microb Genomics. 2021;7: 000703. doi:10.1099/mgen.0.000703

25. Magobo RE, Ismail H, Lowe M, Strasheim W, Mogokotleng R, Perovic O, et al. Outbreak of NDM-1– and OXA-181–Producing Klebsiella pneumoniae Bloodstream Infections in a Neonatal Unit, South Africa. Emerg Infect Dis. 2023;29: 1531–1539. doi:10.3201/eid2908.230484

26. Zaidi AK, Huskins WC, Thaver D, Bhutta ZA, Abbas Z, Goldmann DA. Hospital-acquired neonatal infections in developing countries. The Lancet. 2005;365: 1175–1188. doi:10.1016/S0140-6736(05)71881-X

27. Mukherjee S, Mitra S, Dutta S, Basu S. Neonatal Sepsis: The Impact of Carbapenem-Resistant and Hypervirulent Klebsiella pneumoniae. Front Med. 2021;8: 634349. doi:10.3389/fmed.2021.634349

28. Okomo U, Senghore M, Darboe S, Bojang E, Zaman SMA, Hossain MJ, et al. Investigation of sequential outbreaks of Burkholderia cepacia and multidrug-resistant extended spectrum β-lactamase producing Klebsiella species in a West African tertiary hospital neonatal unit: a retrospective genomic analysis. Lancet Microbe. 2020;1: e119–e129. doi:10.1016/S2666-5247(20)30061-6

29. Meiring S, Mashau R, Magobo R, Perovic O, Quan V, Cohen C, et al. Study protocol for a population-based observational surveillance study of culture-confirmed neonatal bloodstream infections and meningitis in South Africa: Baby GERMS-SA. BMJ Open. 2022;12: e049070. doi:10.1136/bmjopen-2021-049070

30. Egbe FN, Cowden C, Mwananyanda L, Pierre C, Mwansa J, Lukwesa Musyani C, et al. Etiology of Bacterial Sepsis and Isolate Resistance Patterns in Hospitalized Neonates in Zambia. Pediatr Infect Dis J. 2023;42: 921–926. doi:10.1097/INF.0000000000004008

31. Mwananyanda L, Pierre C, Mwansa J, Cowden C, Localio AR, Kapasa ML, et al. Preventing Bloodstream Infections and Death in Zambian Neonates: Impact of a Low-cost Infection Control Bundle. Clin Infect Dis. 2019;69: 1360–1367. doi:10.1093/cid/ciy1114

32. Phillips LT, Bates M, Coffin SE, Foster-Nyarko E, Kapasa M, Machona S, et al. Transmission dynamics of Klebsiella pneumoniae in a neonatal intensive care unit in Zambia before and after an infection control bundle. PLOS Glob Public Health. 2026;6: e0005965. doi:10.1371/journal.pgph.0005965

33. Shuping L, Ismail H, Mashau R, Kwenda S, Holt KE, Magobo RE, et al. Enhanced detection of neonatal invasive infection clusters in South Africa using epidemiological and genomic surveillance data. medRxiv; 2025. p. 2025.11.10.25339895. doi:10.1101/2025.11.10.25339895

34. Aiken AM, Rehman AM, de Kraker ME, Madrid L, Kebede M, Labi A-K, et al. Mortality associated with third-generation cephalosporin resistance in Enterobacterales bloodstream infections at eight sub-Saharan African hospitals (MBIRA): a prospective cohort study. Lancet Infect Dis. 2023;23: 1280–1290. doi:10.1016/S1473-3099(23)00233-5

35. Jain K, Kumar V, Plakkal N, Chawla D, Jindal A, Bora R, et al. Multidrug-resistant

907 sepsis in special newborn care units in five district hospitals in India: a prospective
908 cohort study. Lancet Glob Health. 2025;13: e870–e878. doi:10.1016/S2214-
909 109X(24)00564-3

910 36. Olwagen CP, Izu A, Khan S, Van der Merwe L, Dean NJ, Mabena FC, et al. Genomic
911 relatedness of colonizing and invasive disease Klebsiella pneumoniae isolates in South
912 African infants. Sci Rep. 2025;15: 8043. doi:10.1038/s41598-025-92517-4

913 37. Strysko J, Hu W, Mochankana K, John-Thubuka J, Zankere T, Gopolang B, et al. Using
914 Genomic and Traditional Epidemiologic Approaches to Define Complex Transmission
915 Pathways of Klebsiella pneumoniae Infection in a Neonatal Unit in Botswana, 2022–
916 2023. medRxiv; 2025. p. 2025.11.06.25339637. doi:10.1101/2025.11.06.25339637

917 38. Amulele AV, Orindi B, Ndumba ML, Tigoi C, Omuoyo D, Kahindi E, et al. Genomic
918 epidemiology of Klebsiella pneumoniae neonatal and infant sepsis in Kenyan hospitals.
919 medRxiv; 2025. p. 2025.10.30.25339129. doi:10.1101/2025.10.30.25339129

920 39. Stanton TD, Keegan SP, Abdulahi JA, Amulele AV, Bates M, Heinz E, et al. Distribution
921 of capsule and O types in Klebsiella pneumoniae causing neonatal sepsis in Africa and
922 South Asia: A meta-analysis of genome-predicted serotype prevalence to inform
923 potential vaccine coverage. PLOS Med. 2026;23: e1004879.
924 doi:10.1371/journal.pmed.1004879

925 40. United Nations Statistics Division. Standard Country or Area Codes for Statistical Use
926 (M49). [cited 2 Feb 2026]. Available: https://unstats.un.org/unsd/methodology/m49/

927 41. Lam MMC, Wick RR, Watts SC, Cerdeira LT, Wyres KL, Holt KE. A genomic
928 surveillance framework and genotyping tool for Klebsiella pneumoniae and its related
929 species complex. Nat Commun. 2021;12: 4188. doi:10.1038/s41467-021-24448-3

930 42. Stanton TD, Hetland MAK, Löhr IH, Holt KE, Wyres KL. Fast and accurate in silico
931 antigen typing with Kaptive 3. Microb Genomics. 2025;11: 001428.
932 doi:10.1099/mgen.0.001428

933 43. Argimón S, David S, Underwood A, Abrudan M, Wheeler NE, Kekre M, et al. Rapid
934 Genomic Characterization and Global Surveillance of Klebsiella Using Pathogenwatch.
935 Clin Infect Dis. 2021;73: S325–S335. doi:10.1093/cid/ciab784

936 44. Csardi G, Nepusz T. The igraph software package for complex network research.
937 InterJournal. 2006;Complex Systems: 1695.

938 45. Harris SR. SKA: Split Kmer Analysis Toolkit for Bacterial Genomic Epidemiology.
939 bioRxiv; 2018. p. 453142. doi:10.1101/453142

940 46. Derelle R, Wachsmann J von, Mäklin T, Hellewell J, Russell T, Lalvani A, et al.
941 Seamless, rapid and accurate analyses of outbreak genomic data using Split K-mer
942 Analysis (SKA). bioRxiv; 2024. p. 2024.03.25.586631. doi:10.1101/2024.03.25.586631

943 47. R Core Team. R: A Language and Environment for Statistical Computing. Vienna,
944 Austria: R Foundation for Statistical Computing; 2023. Available: https://www.R-
945 project.org/

946 48. Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical
947 tutorial. Evid Based Ment Health. 2019;22: 153–160. doi:10.1136/ebmental-2019-
948 300117

949 49. Foster-Nyarko E, Cottingham H, Wick RR, Judd LM, Lam MMC, Wyres KL, et al.
950 Nanopore-only assemblies for genomic surveillance of the global priority drug-resistant
951 pathogen, Klebsiella pneumoniae. Microb Genomics. 2023;9: 000936.
952 doi:10.1099/mgen.0.000936

953 50. Gorrie CL, Mirčeta M, Wick RR, Edwards DJ, Thomson NR, Strugnell RA, et al.
954 Gastrointestinal Carriage Is a Major Reservoir of Klebsiella pneumoniae Infection in
955 Intensive Care Patients. Clin Infect Dis Off Publ Infect Dis Soc Am. 2017;65: 208–215.
956 doi:10.1093/cid/cix270

957 51. Regev-Yochay G, Margalit I, Smollan G, Rapaport R, Tal I, Hanage WP, et al. Sink-
958 traps are a major source for carbapenemase-producing Enterobacteriaceae
959 transmission. Infect Control Hosp Epidemiol. 2024;45: 284–291.
960 doi:10.1017/ice.2023.270

961 52. Nakamura I, Yamaguchi T, Miura Y, Watanabe H. Transmission of extended-spectrum
962 β-lactamase-producing Klebsiella pneumoniae associated with sinks in a surgical
963 hospital ward, confirmed by single-nucleotide polymorphism analysis. J Hosp Infect.
964 2021;118: 1–6. doi:10.1016/j.jhin.2021.08.013

965 53. Chapman P, Forde BM, Roberts LW, Bergh H, Vesey D, Jennison AV, et al. Genomic
966 Investigation Reveals Contaminated Detergent as the Source of an Extended-
967 Spectrum-β-Lactamase-Producing Klebsiella michiganensis Outbreak in a Neonatal
968 Unit. J Clin Microbiol. 2020;58: 10.1128/jcm.01980-19. doi:10.1128/jcm.01980-19

969 54. Galdys AL, Marsh JW, Delgado E, Pasculle AW, Pacey M, Ayres AM, et al.
970 Bronchoscope-associated clusters of multidrug-resistant Pseudomonas aeruginosa and
971 carbapenem-resistant Klebsiella pneumoniae. Infect Control Hosp Epidemiol. 2019;40:
972 40–46. doi:10.1017/ice.2018.263

973 55. Pearse O, Lester R, Zuza A, Mangochi H, Siyabu P, Tewesa E, et al. Extended-
974 Spectrum Beta-Lactamase Klebsiella pneumoniae on a Malawian neonatal unit is
975 amplified by neonates and transmitted by maternal hands, cots and ward surfaces.
976 medRxiv; 2025. p. 2025.08.13.25333346. doi:10.1101/2025.08.13.25333346

977 56. Coffin SE, Zaoutis TE. HealthCare–Associated Infections in the Nursery. Infect Dis
978 Fetus Newborn. 2011; 1126–1143. doi:10.1016/B978-1-4160-6400-8.00035-3

979 57. Collins AS. Preventing Health Care–Associated Infections. In: Hughes RG, editor.
980 Patient Safety and Quality: An Evidence-Based Handbook for Nurses. Rockville (MD):
981 Agency for Healthcare Research and Quality (US); 2008. Available:
982 http://www.ncbi.nlm.nih.gov/books/NBK2683/

983 58. Wyres KL, Lam MMC, Holt KE. Population genomics of Klebsiella pneumoniae. Nat
984 Rev Microbiol. 2020;18: 344–359. doi:10.1038/s41579-019-0315-1

985 59. Navon-Venezia S, Kondratyeva K, Carattoli A. Klebsiella pneumoniae: a major
986 worldwide source and shuttle for antibiotic resistance. FEMS Microbiol Rev. 2017;41:
987 252–275. doi:10.1093/femsre/fux013

988 60. Wyres KL, Hawkey J, Hetland MAK, Fostervold A, Wick RR, Judd LM, et al.
989 Emergence and rapid global dissemination of CTX-M-15-associated Klebsiella
990 pneumoniae strain ST307. J Antimicrob Chemother. 2019;74: 577–581.
991 doi:10.1093/jac/dky492

992 61. Tryfinopoulou K, Linkevicius M, Pappa O, Alm E, Karadimas K, Svartström O, et al.
993 Emergence and persistent spread of carbapenemase-producing Klebsiella pneumoniae
994 high-risk clones in Greek hospitals, 2013 to 2022. Eurosurveillance. 2023;28: 2300571.
995 doi:10.2807/1560-7917.ES.2023.28.47.2300571

996 62. Holt KE, Wertheim H, Zadoks RN, Baker S, Whitehouse CA, Dance D, et al. Genomic
997 analysis of diversity, population structure, virulence, and antimicrobial resistance in
998 Klebsiella pneumoniae, an urgent threat to public health. Proc Natl Acad Sci U S A.
999 2015;112: E3574–E3581. doi:10.1073/pnas.1501049112

1000 63. Villa L, Feudi C, Fortini D, Brisse S, Passet V, Bonura C, et al. Diversity, virulence, and
1001 antimicrobial resistance of the KPC-producing Klebsiella pneumoniae ST307 clone.
1002 Microb Genomics. 2017;3: e000110. doi:10.1099/mgen.0.000110

1003 64. Hetland MAK, Hawkey J, Bernhoff E, Bakksjø R-J, Kaspersen H, Rettedal SI, et al.
1004 Within–patient and global evolutionary dynamics of Klebsiella pneumoniae ST17.
1005 Microb Genomics. 2023;9: 001005. doi:10.1099/mgen.0.001005

1006 65. Strydom KA, Chen L, Kock MM, Stoltz AC, Peirano G, Nobrega DB, et al. Klebsiella
1007 pneumoniae ST307 with OXA-181: threat of a high-risk clone and promiscuous plasmid
1008 in a resource-constrained healthcare setting. J Antimicrob Chemother. 2020;75: 896–
1009 902. doi:10.1093/jac/dkz550

1010 66. Okomo U, Gon G, Darboe S, Sey ICM, Nkereuwem O, Leigh L, et al. Assessing the
1011 impact of a cleaning programme on environmental hygiene in labour and neonatal
1012 wards: an exploratory study in The Gambia. Antimicrob Resist Infect Control. 2024;13:
1013 36. doi:10.1186/s13756-024-01393-6

1014 67. Bebell L, Muiru A. Antibiotic use and emerging resistance—how can resource-limited
1015 countries turn the tide? Glob Heart. 2014;9: 347–358. doi:10.1016/j.gheart.2014.08.009

1016 68. Penzias RE, Bohne C, Gicheha E, Molyneux EM, Gathara D, Ngwala SK, et al.
1017 Quantifying health facility service readiness for small and sick newborn care: comparing
1018 standards-based and WHO level-2 + scoring for 64 hospitals implementing with
1019 NEST360 in Kenya, Malawi, Nigeria, and Tanzania. BMC Pediatr. 2024;23: 656.
1020 doi:10.1186/s12887-024-04578-5

1021 69. Nyantakyi E, Baenziger J, Caci L, Blum K, Wolfensberger A, Dramowski A, et al.
1022 Investigating the implementation of infection prevention and control practices in
1023 neonatal care across country income levels: a systematic review. Antimicrob Resist
1024 Infect Control. 2025;14: 8. doi:10.1186/s13756-025-01516-7

1025 70. CDC. Infection Control Assessment and Response (ICAR) Tool for General Infection
1026 Prevention and Control (IPC) Across Settings. In: Healthcare-Associated Infections
1027 (HAIs) [Internet]. 2 Dec 2024 [cited 24 Sept 2025]. Available:
1028 https://www.cdc.gov/healthcare-associated-infections/php/toolkit/icar.html

1029 71. World Health Organization. Infection prevention and control assessment framework at
1030 the facility level. 2018 [cited 24 Sept 2025]. Available:
1031 https://iris.who.int/items/e7b27920-31ab-4e84-afd0-dc36055ca266

1032 72. Hyland P, Jacobs J, Hardy L. The cost of blood cultures: a barrier to diagnosis in low-
1033 income and middle-income countries. Lancet Microbe. 2025;6: 101125.
1034 doi:10.1016/j.lanmic.2025.101125

73. Iregbu K, Zhang R, Zhou Y, Walsh TR. Global health equity and diagnosis of sepsis in low-income and middle-income countries. Lancet Microbe. 2025;6: 101158. doi:10.1016/j.lanmic.2025.101158

74. Vurayai M, Strysko J, Kgomanyane K, Bayani O, Mokomane M, Machiya T, et al. Characterizing the bioburden of ESBL-producing organisms in a neonatal unit using chromogenic culture media: a feasible and efficient environmental sampling method. Antimicrob Resist Infect Control. 2022;11: 14. doi:10.1186/s13756-021-01042-2

75. World Health Organization. The WHO AWaRe (Access, Watch, Reserve) antibiotic book. 2022 [cited 4 Nov 2025]. Available: https://www.who.int/publications/i/item/9789240062382

76. Verani JR, Blau DM, Gurley ES, Akelo V, Assefa N, Baillie V, et al. Child deaths caused by Klebsiella pneumoniae in sub-Saharan Africa and south Asia: a secondary analysis of Child Health and Mortality Prevention Surveillance (CHAMPS) data. Lancet Microbe. 2024;5: e131–e141. doi:10.1016/S2666-5247(23)00290-2

77. Okomo UA, Darboe S, Bah SY, Ayorinde A, Jarju S, Sesay AK, et al. Maternal colonization and early-onset neonatal bacterial sepsis in the Gambia, West Africa: a genomic analysis of vertical transmission. Clin Microbiol Infect. 2023;29: 386.e1-386.e9. doi:10.1016/j.cmi.2022.10.012

Supporting Information Captions

S1 Table. Ethics committees approving individual studies. Approval for the analysis presented here was granted by the Observational / Interventions Research Ethics Committee of the London School of Hygiene and Tropical Medicine (ref #29931), and covers inclusion of data from the studies whose primary ethical approvals are listed in this table.

S2 Table. Studies included in the analysis. Details of type of study, number of isolates; laboratory methods for identification, storage, DNA extraction, sequencing; informatics methods for quality control and assembly; BioProject accession and citation/s for primary study.

S3 Table. Isolates and sequence data included in the study.

S4 Table. Clusters identified in the study.

S5 Table. Summary of *Klebsiella pneumoniae* STs identified in the study.

S6 Table. Chi squared tests of resistance distribution by cluster status. Only one isolate was included per cluster, and the representative cluster isolate was assigned the consensus ESBL or carbapenemase status for that cluster (e.g. if 3 of 4 cases in the cluster were ESBL, the cluster was recorded as ESBL-positive).

S7 Table. Logistic regression model for transmission. Multivariable logistic regression model to assess factors associated with transmission clusters. Each unique ‘introduction’ (i.e. cluster, or

unclustered singleton case) was treated as an observation, with the outcome recorded as transmission (cluster size ≥2) or no transmission (unclustered singleton case). For each cluster, each predictor was assigned the consensus value for that cluster (e.g. if 3 of 4 cases were ESBL, the cluster was recorded as ESBL). Predictors ST, Site, K locus, and O type were encoded categorical variables. AMR variables (ESBL gene and carbapenemase gene presence) were encoded as binary. Commonly transmitted STs were defined as those that were identified in ≥3 transmission clusters in two or more sites; other STs were categorised as 'Other' and used as the reference category. The top 10 K loci were encoded as individual categories and compared to all other K loci as the reference category. O types were compared to the most common O type (51.6%) as the reference category. ESBL+: ESBL or carbapenemase gene carriage (Kleborate resistance score ≥ 1); CP+: carbapenemase gene carriage (Kleborate resistance score ≥ 2).

S8 Table. Chi squared tests of resistance distribution by ST type. Only one isolate was included per cluster, and the representative cluster isolate was assigned the consensus ESBL or carbapenemase status for that cluster (e.g. if 3 of 4 cases in the cluster were ESBL, the cluster was recorded as ESBL-positive).

S9 Table. Summary of O serogroups detected. Only one isolate was counted per cluster, and the representative cluster isolate was assigned the consensus ESBL or carbapenemase status for that cluster (e.g. if 3 of 4 cases in the cluster were ESBL, the cluster was recorded as ESBL-positive).

S10 Table. Summary of K loci detected. Only one isolate was counted per cluster, and the representative cluster isolate was assigned the consensus ESBL or carbapenemase status for that cluster (e.g. if 3 of 4 cases in the cluster were ESBL, the cluster was recorded as ESBL-positive).

S1 Figure. Flow diagram for inclusion of isolates. All numbers shown represent the number of isolates. For the line 'Sites with N<10 pass filters', the numbers represent the total number of isolates excluded for all excluded sites.

S2 Figure. Geotemporal distribution of isolates included in the analysis. (A) Location of study sites. Each point represents a unique site and point sizes indicate the number of isolates included per site, as per figure legend. Country colours indicate the number of isolates included per country, as per figure legend. The map was generated using the rnaturalearth (version 1.0.1) package in R. Base map source: Natural Earth, https://www.naturalearthdata.com/downloads/10m-cultural-vectors/, accessed using rnaturalearth R package v1.0.1, terms of use: https://www.naturalearthdata.com/about/terms-of-use/. (B) Plot shows sampling dates for all isolates included per sites. Each point represents a unique isolate included per site and numbers inside the box represent the number of isolates per site. Points are jittered along the y-axis to aid visibility.

S3 Figure. Transmission clusters of *K. pneumoniae* neonatal sepsis cases per study. Each point represents one or more cases isolated on specific dates. Points are coloured according to sequence type. Clusters are represented as groups of cases (points) linked by horizontal lines. Clusters belonging to the same sequence type are jittered along the y-axis to allow visibility of overlapping clusters. ST – sequence type. * – includes single locus variants of the respective STs.

S4 Figure. Sensitivity of the cluster proportion estimates to varying temporal and genetic distance thresholds. The sub-panels show estimates for individual study datasets at different combinations of genetic distance threshold (x-axis) and temporal distance threshold ranges (as per figure legend).

S5 Figure. Cluster proportion vs facility characteristics. (A) Individual site characteristics and estimates of proportion of cases in clusters. (B) Distribution of cluster proportion estimates by facility

characteristics. Panels compare the distribution of proportion of isolates in clusters across different facility characteristics: (i) Onsite availability of neonatal surgical facilities (ii) Facility size (iii) Availability of piped water (iv) Number of neonatal beds. Individual points represent cluster proportions for specific facilities. Facility size – Small: 50–150 beds, Medium: 151–300 beds, Large: 301–600 beds, Very Large: >600 beds. CI: confidence interval

S1 Appendix. Sensitivity of cluster analysis.

S1 Checklist. STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) Statement – checklist of items that should be included in reports of observational studies, available at https://www.strobe-statement.org/, licenced under CC BY 4.0.

Financial Disclosure Statement

This study was supported by the Gates Foundation [https://www.gatesfoundation.org/] (grants INV049364, INV025280, INV077266 to KEH; INV049641 to KLW; INV003519 to AMA; INV005180 to NAF; INV041685 to JAB; INV008112 to NPG; INV005567 to CCT; INV005691 to DHH; INV005773 to SAM; INV065400 to AMM; INV065400 to SEC), the Fleming Fund [https://www.flemingfund.org/] (grant FF25-286 for SeqAfrica to support sequencing capacity at KCRI), the Thrasher Research Fund [https://www.thrasherresearch.org/] (grant #12036 to DHH), the Center for AIDS Research [https://www.niaid.nih.gov/research/centers-aids-research] (core support grant to SEC), the Wellcome Trust [https://wellcome.org] (grant 217303/Z/19/Z to EH, core support grants 206194 to WSI, 206454 to MLW, 203077/Z/16/Z to KWTRP), and the National Health and Medical Research Council of Australia [https://www.nhmrc.gov.au/] (APP1176192 to KLW). Pfizer [https://www.pfizer.com/] sponsored the sequencing of a subset of isolates from the GBS-COP study for WITS-Vida (SAM). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The conclusions and opinions expressed in this work are those of the author(s) alone and shall not be attributed to any funder. Under the grant conditions of the Gates Foundation and Wellcome Trust, a Creative Commons Attribution 4.0 License has already been assigned to the Author Accepted Manuscript version that might arise from this submission. Please note works submitted as a preprint have not undergone a peer review process.

Author contribution statement

Conceptualization: Kathryn E Holt
Data Curation: Jabir A Abdulahi, Anne V Amulele, Matthew Bates, Eva Heinz, Weiming Hu, Kajal Jain, Rindidzani Magobo, Courtney P Olwagen, John M Tembo, Tolbert Sonda, Jonathan Strysko, Caroline C Tigoi
Formal Analysis: Erkison Ewomazino Odih, Kathryn E Holt
Funding Acquisition: Ramesh K Agarwal, Alexander M Aiken, James A Berkley, Susan E Coffin, Nicholas A Feasey, Nelesh P Govender, Davidson H Hamer, Kathryn E Holt, Shabir A Madhi, M Jeeva Sankar, Kelly L Wyres
Investigation: Kyle Bittinger, Jennifer Cornick, Ebenezer Foster-Nyarko, Wilson Gumbi, Steven M Jones, Chileshe Lukwesa, Carolyn M McGann, Ahmed M Moustafa, Patrick Musicha, James CL Mwansa, Moreka L Ndumba, Donwilliams O Omuoyo, Oliver Pearse, Laura T Phillips, Paul J Planet, Charlene MC Rodrigues, Fatou Secka, Kirsty Sands, Jonathan Strysko, Erin Theiller, Allan M Zuza
Methodology: Erkison Ewomazino Odih, Kathryn E Holt, Kelly L Wyres
Resources: Sulagna Basu, Grace J Chan, Kenneth C Iregbu, Jean-Baptiste Mazarati, Semaria Solomon Alemayehu, Timothy R Walsh, Rabaab Zahra, Kajal Jain, Angela Dramowski, Sombo Fwoloshi, Appiah-Korang Labi, Lola Madrid, Noah Obeng-Nkrumah, David Ojok, Boaz D Wadugu, Andrew C Whitelaw, Anudita Bhargava, Atul Jindal, Ramesh K Agarwal, M Jeeva Sankar, Alexander M Aiken, James A Berkley, Susan E Coffin, Nicholas A Feasey, Nelesh P Govender, Davidson H Hamer, Shabir A Madhi,
Software: Erkison Ewomazino Odih, Thomas D Stanton
Supervision: Sulagna Basu, Grace J Chan, Kenneth C Iregbu, Jean-Baptiste Mazarati, Semaria Solomon Alemayehu, Timothy R Walsh, Rabaab Zahra, Kajal Jain, Angela Dramowski, Sombo Fwoloshi, Appiah-Korang Labi, Lola Madrid, Noah Obeng-Nkrumah, David Ojok, Boaz D Wadugu, Andrew C Whitelaw, Anudita Bhargava, Atul Jindal, Ramesh K Agarwal, M Jeeva Sankar, Alexander M Aiken, James A Berkley, Susan E Coffin, Nicholas A Feasey, Nelesh P Govender, Davidson H Hamer, Shabir A Madhi,
Visualization: Erkison Ewomazino Odih, Kathryn E Holt
Writing – Original Draft Preparation: Erkison Ewomazino Odih, Kathryn E Holt
Writing – Review & Editing: All authors.